Pacira BioSciences (PCRX) Total Non-Current Liabilities (2010 - 2026)
Pacira BioSciences (PCRX) posted quarterly Total Non-Current Liabilities of $530.0 million for Q1 2026, down 30.65% year-over-year from $764.3 million in Q1 2025, and down 3.85% quarter-over-quarter from $551.2 million in Q4 2025.
Pacira BioSciences (PCRX) Total Non-Current Liabilities (2010 - 2026) Analysis & Trends
Pacira BioSciences' Total Non-Current Liabilities history runs 17 years deep, the most recent figure standing at $530.0 million for Q1 2026.
- In Q1 2026, Total Non-Current Liabilities fell 30.65% year-over-year to $530.0 million; the TTM figure through Mar 2026 stood at $530.0 million (down 30.65% YoY), while the FY2025 annual figure was $551.2 million, down 27.31% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $530.0 million, down from $551.2 million in the prior quarter.
- The five-year high for Total Non-Current Liabilities was $1.2 billion in Q1 2022, with the low at $530.0 million in Q1 2026.
- The 5-year median for Total Non-Current Liabilities is $754.3 million (2025), against an average of $759.7 million.
- The sharpest annual moves came in 2022 and 2023: Total Non-Current Liabilities soared 85.48% in 2022, then tumbled 36.49% in 2023.
- Pacira BioSciences' Total Non-Current Liabilities stood at $896.5 million in 2022, then slipped by 22.96% to $690.7 million in 2023, then gained by 9.8% to $758.4 million in 2024, then retreated by 27.31% to $551.2 million in 2025, then decreased by 3.85% to $530.0 million in 2026.
- Business Quant data shows PCRX's Total Non-Current Liabilities at $530.0 million in Q1 2026, $551.2 million in Q4 2025, and $545.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - | -13.28 Bn |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn | 16.45 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn | 11.64 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn | 33.50 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn | 607.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn | 18.76 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn | 1.37 Bn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn | 6.42 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - | 334.00 Mn |
| 10 | Pacira BioSciences | 939.59 Mn | 688.56 Mn | 148.24 Mn | 545.35 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 545.35 Mn |
| Mar 31, 2026 | 530.03 Mn |
| Dec 31, 2025 | 551.23 Mn |
| Sep 30, 2025 | 545.06 Mn |
| Jun 30, 2025 | 754.34 Mn |
| Mar 31, 2025 | 764.26 Mn |
| Dec 31, 2024 | 758.35 Mn |
| Sep 30, 2024 | 759.32 Mn |
| Jun 30, 2024 | 754.54 Mn |
| Mar 31, 2024 | 678.47 Mn |
| Dec 31, 2023 | 690.68 Mn |
| Sep 30, 2023 | 690.97 Mn |
| Jun 30, 2023 | 722.62 Mn |
| Mar 31, 2023 | 743.80 Mn |
| Dec 31, 2022 | 896.52 Mn |
| Sep 30, 2022 | 945.13 Mn |
| Jun 30, 2022 | 957.88 Mn |
| Mar 31, 2022 | 1.17 Bn |
| Dec 31, 2021 | 1.32 Bn |
| Sep 30, 2021 | 629.85 Mn |